Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: A prospective cohort study in ankylosing spondylitis

Arthritis and Rheumatism

Volumn 60, Issue 5, 2009, Pages 1324-1330

  Van Eijk, I C ^a   De Vries, M K ^b   Levels, J H M ^c   Peters, M J L ^b   Huizer, E E ^a   Dijkmans, B A C ^a   Van Der Horst Bruinsma, I E ^b   Hazenberg, B P C ^d   Van De Stadt, R J ^a   Wolbink, G J ^a   Nurmohamed, M T ^a  

^a JAN VAN BREEMEN INSTITUTE   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; ETANERCEPT; FAS ANTIGEN; HIGH DENSITY LIPOPROTEIN; LIPID; SERUM AMYLOID A; TUMOR NECROSIS FACTOR;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEART PROTECTION; HUMAN; LIPID BLOOD LEVEL; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

ADULT; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; COHORT STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; SERUM AMYLOID A PROTEIN; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 66049109843     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.24492     Document Type: Article

References (40)

1. Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A, et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998;41:58-67.
2. Lautermann D, Braun J. Ankylosing spondylitis - cardiac manifestations. Clin Exp Rheumatol 2002;20(6 Suppl 28):S11-S15.
3. Lehtinen K. Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis 1993;52: 174-176
4. Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 2004;34:585-592
5. Roldan CA, Chavez J, Wiest PW, Qualls CR, Crawford MH. Aortic root disease and valve disease associated with ankylosing spondylitis. J Am Coll Cardiol 1998;32:1397-1404
6. Divecha H, Sattar N, Rumley A, Cherry L, Lowe GD, Sturrock R. Cardiovascular risk parameters in men with ankylosing spondylitis in comparison with non-inflammatory control subjects: relevance of systemic inflammation. Clin Sci Lond 2005;109:171-176
7. Heeneman S, Daemen MJ. Cardiovascular risks in spondyloarthritides. Curr Opin Rheumatol 2007;19:358-362
8. Joven J, Rubies-Prat J, Ras MR, de la Figuera M, Lience E, Masdeu S. High density lipoprotein cholesterol subfractions and apoprotein A-I in patients with rheumatoid arthritis and ankylosing spondylitis [letter]. Arthritis Rheum 1984;27:1199-1200
9. Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006;33:2167-2172
10. Van Halm VP, van Denderen JC, Peters MJ, Twisk JW, van der PM, van der Horst-Bruinsma IE, et al. Increased disease activity is associated with a deteriorated lipid profile in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:1473-1477
11. Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold KR, et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004;45:1169-1196
12. Navab M, Anantharamaiah GM, Fogelman AM. The role of high-density lipoprotein in inflammation. Trends Cardiovasc Med 2005;15:158-161
13. Memon RA, Grunfeld C, Moser AH, Feingold KR. Tumor necrosis factor mediates the effects of endotoxin on cholesterol and triglyceride metabolism in mice. Endocrinology 1993;132: 2246-2253
14. Kiortsis DN, Mavridis AK, Filippatos TD, Vasakos S, Nikas SN, Drosos AA. Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 2006;33:921-923
15. Popa C, Barrea P, Netea MG, Stalenhoef AF, van der Meer JW. Anti-TNF therapy and plasma HDL cholesterol concentration [letter]. Atherosclerosis 2005;182:375.
16. Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC Jr, Dijkmans B, et al, ASsessment in AS International Working Group and the European League Against Rheumatism. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006;65:442-452
17. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a propsal for modification of the New York criteria. Arthritis Rheum 1984;27:361-368
18. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in aknylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-2291
19. Hazenberg BP, Limburg PC, Bijzet J, van Rijswijk MH. Monoclonal antibody based ELISA for human SAA. In: Natvig JB, Forre O, Husby G, Husebekk A, Skogen B, Sletten K, et al, editors. Amyloid and amyloidosis. Dordrecht (The Netherlands): Kluwer Academic Publishers; 1991. p. 898-901.
20. Levels JH, Bleijlevens B, Rezaee F, Aerts JM, Meijers JC. SELDI-TOF mass spectrometry of high-density lipoprotein. Proteome Sci 2007;5:15.
21. Ducret A, Bruun CF, Bures EJ, Marhaug G, Husby G, Aebersold R. Characterization of human serum amyloid A protein isoforms separated by two-dimensional electrophoresis by liquid chromatography/ electrospray ionization tandem mass spectrometry. Electrophoresis 1996;17:866-876
22. Van der Steeg WA, Boekholdt SM, Stein EA, El Harchaoui K, Stroes ES, Sandhu MS, et al. Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk. Ann Intern Med 2007;146: 640-648
23. Ingelsson E, Schaefer EJ, Contois JH, McNamara JR, Sullivan L, Keyes MJ, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 2007;298:776-785
24. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001;358:2026-2033
25. Rasouli M, Kiasari AM, Mokhberi V. The ratio of apoB/apoAI, apoB and lipoprotein(a) are the best predictors of stable coronary artery disease. Clin Chem Lab Med 2006;44:1015-1021
26. Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001;104: 1108-1113
27. Rezaee F, Casetta B, Levels JH, Speijer D, Meijers JC. Proteomic analysis of high-density lipoprotein. Proteomics 2006;6:721-730
28. Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, Cheung MC, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007;117:746-756
29. Van der Westhuyzen DR, de Beer FC, Webb NR. HDL cholesterol transport during inflammation. Curr Opin Lipidol 2007;18: 147-151
30. Han CY, Chiba T, Campbell JS, Fausto N, Chaisson M, Orasanu G, et al. Reciprocal and coordinate regulation of serum amyloid A versus apolipoprotein A-I and paraoxonase-1 by inflammation in murine hepatocytes. Arterioscler Thromb Vasc Biol 2006;26: 1806-1813.
31. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342: 836-843
32. Eriksen N, Benditt EP. Isolation and characterization of the amyloid-related apoprotein (SAA) from human high density lipoprotein. Proc Natl Acad Sci U S A 1980;77:6860-6864
33. Coetzee GA, Strachan AF, van der Westhuyzen DR, Hoppe HC, Jeenah MS, de Beer FC. Serum amyloid A-containing human high density lipoprotein 3: density, size, and apolipoprotein composition. J Biol Chem 1986;261:9644-9651
34. Van Leuven SI, Hezemans R, Levels JH, Snoek S, Stokkers PC, Hovingh GK, et al. Enhanced atherogenesis and altered high density lipoprotein in patients with Crohn's disease. J Lipid Res 2007;48:2640-2646
35. Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, et al. Anti-inflammatory HDL becomes proinflammatory during the acute phase response: loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995;96:2758-2767
36. Steinmetz A, Hocke G, Saile R, Puchois P, Fruchart JC. Influence of serum amyloid A on cholesterol esterification in human plasma. Biochim Biophys Acta 1989;1006:173-178
37. Hoffman JS, Benditt EP. Plasma clearance kinetics of the amyloid-related high density lipoprotein apoprotein, serum amyloid protein (apoSAA), in the mouse: evidence for rapid apoSAA clearance. J Clin Invest 1983;71:926-934
38. De Beer FC, Connell PM, Yu J, de Beer MC, Webb NR, van der Westhuyzen DR. HDL modification by secretory phospholipase A(2) promotes scavenger receptor class B type I interaction and accelerates HDL catabolism. J Lipid Res 2000;41:1849-1857.
39. Tietge UJ, Maugeais C, Cain W, Grass D, Glick JM, de Beer FC, et al. Overexpression of secretory phospholipase A(2) causes rapid catabolism and altered tissue uptake of high density lipoprotein cholesteryl ester and apolipoprotein A-I. J Biol Chem 2000;275: 10077-10084
40. De Beer FC, de Beer MC, van der Westhuyzen DR, Castellani LW, Lusis AJ, Swanson ME, et al. Secretory non-pancreatic phospholipase A2: influence on lipoprotein metabolism. J Lipid Res 1997;38:2232-2239